EUVIMEDEUVIMED entdecken
Multizentrische Studie

HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18‐positive patients: A prospective multicenter study with a 2‐year follow up

Yang Cao, Xiaoping Xiao, Dandan Liang, Ye Lu, Chongdong Liu, Hua Li, Wei Wang, Junjun Yang, Jinhui Wang, Yan Li, Caijuan Li, Ruoli Guan und 9 weitere

International Journal of Gynecology & Obstetrics · 2025-02 · 168 (2) · 545-550

DOI: 10.1002/ijgo.15897 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 08.09.2024. Verfasst von Yang Cao und 20 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospita…. Hauptthemen laut MEDLINE: Human papillomavirus 16, Uterine Cervical Dysplasia, Papillomavirus Infections, Uterine Cervical Neoplasms. Die Arbeit nennt 14 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the effectiveness of HPV 16/18 E7 oncoprotein in detecting high‐grade cervical intraepithelial neoplasia (CIN) and predicting disease outcomes in HPV 16/18‐positive patients.

Methods

The present study was a cross‐sectional study with a 2‐year follow up. We collected 915 cervical exfoliated cell samples from patients who tested positive for HPV 16/18 in gynecologic clinics of three tertiary hospitals in Beijing from March 2021 to October 2022 for HPV 16/18 E7 oncoprotein testing. Subsequently, 2‐year follow up of 408 patients with baseline histologic CIN1 or below were used to investigate the predictive role of HPV 16/18 E7 oncoprotein in determining HPV persistent infection and disease progression.

Results

The positivity rate of the HPV 16/18 E7 oncoprotein assay was 42.06% (249/592) in the inflammation/CIN 1 group and 85.45% (277/324) in the CIN2+ group. For CIN2+ detection, using the HPV 16/18 E7 oncoprotein assay combined with HPV 16/18 testing, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 85.45%, 57.94%, 52.57%, and 87.95%, respectively. During the 2‐year follow up, the sensitivity, specificity, PPV, and NPV for predicting persistent HPV infection were 48.44%, 58.21%, 34.64%, and 71.18% in the baseline inflammation and CIN1 group.

Conclusions

As a triage method for high‐grade CIN screening in HPV 16/18‐positive patients, HPV 16/18 E7 oncoprotein demonstrated a relatively high NPV, making it suitable for clinical use in triaging HPV 16/18‐positive cases and potentially reducing the colposcopic referral rate. HPV 16/18 E7 oncoprotein exhibited a preferably predictive value in determining HPV infection outcomes and disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human papillomavirus 16Uterine Cervical DysplasiaPapillomavirus InfectionsUterine Cervical NeoplasmsHuman papillomavirus 18TriageOncogene Proteins, ViralPapillomavirus E7 ProteinsHumansFemaleAdultProspective StudiesCross-Sectional StudiesFollow-Up StudiesMiddle AgedPredictive Value of TestsYoung AdultDisease ProgressionEarly Detection of CancerDNA-Binding Proteins

Stichwörter der Autor:innen

2‐year follow upHPV 16/18 E7 oncoproteincervical intraepithelial neoplasiahigh‐risk human papillomaviruspredictive valuetriage effect

Substanzen

Oncogene Proteins, ViralPapillomavirus E7 Proteinsoncogene protein E7, Human papillomavirus type 16E7 protein, Human papillomavirus type 18DNA-Binding Proteins

Autor:innen und Institutionen

  • National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,…
  • Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China.
  • Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

ORCID-Profile: Honghui Shi

Förderung

  • National High Level Hospital Clinical Research

Zitieren

APA

Cao, Y., Xiao, X., Liang, D., Lu, Y., Liu, C., Li, H., Wang, W., Yang, J., Wang, J., Li, Y., Li, C., Guan, R., Zhang, D., Bi, H., Zhang, L., Qu, H., Xu, T., Zhang, Y., Wang, J., …, & Shi, H. (2025). HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18‐positive patients: A prospective multicenter study with a 2‐year follow up. International Journal of Gynecology & Obstetrics, 168(2), 545-550. https://doi.org/10.1002/ijgo.15897

Vancouver

Cao Y, Xiao X, Liang D, Lu Y, Liu C, Li H, et al. HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18‐positive patients: A prospective multicenter study with a 2‐year follow up. International Journal of Gynecology & Obstetrics. 2025;168(2):545-550. doi:10.1002/ijgo.15897

BibTeX
@article{Cao2025,
  author = {Cao, Yang and Xiao, Xiaoping and Liang, Dandan and Lu, Ye and Liu, Chongdong and Li, Hua and Wang, Wei and Yang, Junjun and Wang, Jinhui and Li, Yan and Li, Caijuan and Guan, Ruoli and Zhang, Dai and Bi, Hui and Zhang, Lei and Qu, Hong and Xu, Tao and Zhang, Ying and Wang, Jin and Song, Shuhui and Shi, Honghui},
  title = {HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18‐positive patients: A prospective multicenter study with a 2‐year follow up},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2025},
  volume = {168},
  number = {2},
  pages = {545--550},
  doi = {10.1002/ijgo.15897}
}
Kostenlos starten →